EICHORCondition: Overactive Bladder · Sponsor: Urovant Sciences GmbH
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Urology Centers of Alabama | Homewood, Alabama, United States | — |
| 43rd Medical Associates | Phoenix, Arizona, United States | — |
| Fiel Family and Sports Medicine, PC | Tempe, Arizona, United States | — |
| Arkansas Urology Associates, PA | Little Rock, Arkansas, United States | — |
| Golden Gate Urology | Berkley, California, United States | — |
| Urology Associates of Norwalk | Norwalk, Connecticut, United States | — |
| Urological Research Network | Hialeah, Florida, United States | — |
| University of Florida Health Jacksonville Facility Clinic | Jacksonville, Florida, United States | — |
| University of Miami Miller School of Medicine | Miami, Florida, United States | — |
| South Florida Research Phase I-IV, Inc. | Miami Springs, Florida, United States | — |
| Tampa Urology Partners LLP | Tampa, Florida, United States | — |
| Florida Urology Partners | Tampa, Florida, United States | — |
+ 52 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05067478